Celgene to Present Results of Two P-III Trial SUNBEAM and RADIANCE Part B for Ozanimod to Treat RMS at ECTRIMS 2018
Shots:
- The two P-III trials SUNBEAM (N=1346) and RADIANCE (N=1320) involves assessing of two doses of ozanimod PO (0.92 & 0.46 mg- equivalent to 1 & 0.5 mg ozanimod HCI) vs 1L Avonex in RMS patients for @12 mos. & @24 mos. respectively
- P-III SUNBEAM & RADIANCE Part B results: early & advance RMS (1 &0.5mg vs IFN): ARR@12mos. (0.149-0.217; 0.200- 0.277 vs 0.285-0.363); mean number of gadolinium-enhancing(GdE) (0.263- 0.278; 0.458- 0.32 vs 0.656- 0.915); mean number of new or enlarging T2 lesions (2.952- 2.514; 3.744- 2.903 vs 4.633- 4.710)
- Ozanimod is PO sphingosine 1-phosphate 1 (S1P1) and 5 (S1P5) receptor modulator indicated to treat RMS- UC and Crohn's disease. Avonex (IFN) is a interferon beta-1a used to treat MS
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
